Follow-On Biologics Bill IP Provisions Are “Unfavorable” – Wyeth Attorney
Executive Summary
The follow-on biologics bill recently unveiled by Rep. Henry Waxman (D-Calif.) and Sen. Chuck Schumer (D-N.Y.) would create an "unfavorable" intellectual property environment for innovators, Wyeth Senior Regulatory Attorney Cecilia Burke suggests
You may also be interested in...
Follow-On Biologics Could Save Medicare $14 Bil. Over 10 Years – PCMA
Creating a way for FDA to approve follow-on biologics could lead to savings of more than $14 billion for Medicare Part B from fiscal 2007 to 2016, according to a "preliminary assessment" that the Pharmaceutical Care Management Association released Jan. 4
Follow-On Biologics Could Save Medicare $14 Bil. Over 10 Years – PCMA
Creating a way for FDA to approve follow-on biologics could lead to savings of more than $14 billion for Medicare Part B from fiscal 2007 to 2016, according to a "preliminary assessment" that the Pharmaceutical Care Management Association released Jan. 4
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act